Zealand Pharma A/S has entered into a global license agreement with Novo Nordisk A/S to commercialize Zegalogue for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes.
Zealand Pharma A/S announced it has entered into a global license and development agreement with Novo Nordisk A/S to commercialize Zegalogue (dasiglucagon) for injection
Zegalogue is approved by the FDA for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 and above.
Under the terms of the agreement, Zealand will receive an upfront payment of DKK 25 million and is eligible to receive up to DKK 45 million in near-term development, regulatory and manufacturing-based milestones. Zealand is also eligible to receive up to DKK 220 million in sales-based milestones and tiered royalties ranging from high single-digit to low double-digit percentages on worldwide net sales of Zegalogue to be marketed by Novo Nordisk. Zealand will be responsible for certain planned regulatory, development and manufacturing activities to support further development and approval outside of the U.S. Zealand will retain all non-licensed intellectual property rights to the company’s other dasiglucagon development programs.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins